Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Last trade$13.81
Day change-$0.84 (-5.73%)
Day range$13.29 – $15.02
Volume113,036
Market cap$469M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$469.03M
Price / earnings
—
Price / book
2.43×
Price / sales
31,268.68×
EV / sales
25,131.81×
EV / EBITDA
-1.94×
Profitability
Earnings per share
-$7.97
Return on assets
-93.17%
Return on equity
-132.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.02×
Quick ratio
4.02×
Cash ratio
1.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$139.97M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LYEL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3K
$4K
$2K
$6K
$15K
$8K
$7K
$11K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$3K
$4K
$2K
$6K
$15K
$8K
$7K
$11K
Selling, general and administrative
$9.3M
$9.58M
$9.56M
$10.62M
$10.69M
$9.79M
$14.05M
$14.52M
Research and development
$40.9M
$39.52M
$36.6M
$52.2M
$28.17M
$34.86M
$43.45M
$48.67M
Total operating expenses
$48.3M
$47.34M
$44.26M
$129.8M
$37.27M
$47.15M
$57.37M
$204.47M
Operating income
-$48.3M
-$47.34M
-$44.26M
-$129.79M
-$37.25M
-$47.14M
-$57.37M
-$204.46M
Interest expense
$1.91M
$2.18M
$2.19M
$0
$3.27M
$3.28M
$3.86M
$0
Income before taxes
-$45.53M
-$44.76M
-$24.15M
-$140.72M
-$38.85M
-$42.68M
-$52.2M
-$191.94M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$45.53M
-$44.76M
-$24.15M
-$140.72M
-$38.85M
-$42.68M
-$52.2M
-$191.94M
Net income attributable to common shareholders
-$45.53M
-$44.76M
-$24.15M
-$140.72M
-$38.85M
-$42.68M
-$52.2M
-$191.94M
EBITDA
-$46.24M
-$45.12M
-$41.93M
-$61.06M
-$34.69M
-$42.56M
-$53.93M
-$60.95M
Basic earnings per share
-$1.86
-$1.92
-$1.10
-$6.85
-$2.13
-$2.89
-$3.54
-$13.71
Diluted earnings per share
-$1.86
-$1.92
-$1.10
-$6.85
-$2.13
-$2.89
-$3.54
-$13.71
Recent news
Company coverage with links to the original publishers.
Lyell Immunopharma (LYEL) has gained 76.1% over the past four weeks and closed at $14.30. Wall Street analysts have set a mean price target of $35.50, indicating 148.3% upside potential. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions.
Lyell Immunopharma announced updated safety data for ronde-cel, its dual-targeting CD19/CD20 CAR T-cell therapy, showing no Grade ≥3 cytokine release syndrome and low Grade ≥3 neurotoxicity rates in over 100 patients with relapsed/refractory large B-cell lymphoma. Translational data revealed enhanced memory potential of CAR T cells and durable responses, particularly in patients with low antigen expression. The company expects pivotal trial data in mid-2027 with BLA submission to follow.
Lyell Immunopharma announced positive safety data for LYL273, its GCC-targeted CAR T-cell therapy for metastatic colorectal cancer. Gastrointestinal prophylaxis significantly reduced Grade ≥2 diarrhea/colitis from 55% to 10%, with no Grade ≥3 cytokine release syndrome or neurotoxicity observed. The Phase 1 trial has been amended to Phase 1/2 design to enable seamless expansion into a potential pivotal Phase 2 trial, with an End-of-Phase 1 FDA meeting expected by end of 2026.
Lyell Immunopharma closed an additional $50 million tranche from its $100 million equity private placement following achievement of a clinical milestone for rondecabtagene autoleucel (ronde-cel) in its PiNACLE pivotal trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer. With this funding, Lyell expects sufficient cash runway into Q2 2027.
Century Therapeutics announced the appointments of Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, bringing extensive experience in biotechnology, corporate development, and life science investment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.